Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riociguat - Bayer

Drug Profile

Riociguat - Bayer

Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Antifibrotics; Carbamates; Diamines; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Systemic scleroderma
  • No development reported Raynaud's disease

Most Recent Events

  • 22 Feb 2023 No development reported - Phase-III for Pulmonary hypertension in Sweden, Greece, Ireland, Netherlands, United Kingdom, Spain, Slovakia, Portugal, Poland, Italy, Germany, Denmark, Czech Republic, Belgium, Austria, Thailand (PO) (Bayer pipeline, February 2023)
  • 17 Feb 2021 No development reported - Phase-II for Raynaud's disease in Germany (PO) (Bayer website, February 2020)
  • 08 Sep 2020 Efficacy and safety data from the phase III PATENT-1 trial in Pulmonary arterial hypertension release by Bayer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top